Polar body-based PGT-A: not dead yet? A step forward back to the roots of PGT-A.
Aneuploidy
IVF
Intracytoplasmic sperm injection
Polar body
Preimplantation genetic testing for aneuploidies
Trophectoderm
Journal
Reproductive biomedicine online
ISSN: 1472-6491
Titre abrégé: Reprod Biomed Online
Pays: Netherlands
ID NLM: 101122473
Informations de publication
Date de publication:
30 Aug 2024
30 Aug 2024
Historique:
received:
28
07
2024
revised:
19
08
2024
accepted:
19
08
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
27
10
2024
Statut:
aheadofprint
Résumé
Trophectoderm-based preimplantation genetic testing for aneuploidies (PGT-A) is used worldwide as a means of selecting embryos with high potential for achieving a live birth. However, trophectoderm analysis may be impaired through embryonic mosaicism, leading to genetically healthy embryos being falsely discarded, and thus even reducing cumulative live birth rates. Polar body biopsy, a technique applied since the early days of preimplantation testing, has been abandoned by most IVF centres. In comparison to trophectoderm analysis, however, polar body biopsy might even have certain advantages over trophectoderm PGT-A. This Countercurrent contribution discusses the newest clinical evidence, as well as ethical and cost-efficiency considerations, and argue that polar body analysis should be reconsidered.
Identifiants
pubmed: 39462706
pii: S1472-6483(24)00619-9
doi: 10.1016/j.rbmo.2024.104430
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104430Informations de copyright
Copyright © 2024 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.